The biopharma world kicks off each year with a frenzy of activity at JP Morgan. Endpoints has been there to chronicle it with wall-to-wall coverage, and our founder and editor John Carroll has convened top newsmakers to provide detailed insights about their strategies.
For #JPM22, Endpoints is expanding on our proud tradition with multiple panels addressing the most important issues in biopharma R&D.
Monday
Tuesday
Wednesday
With a big assist from the FDA, which has been quick to greenlight anything that looks like it might help dying cancer patients, the industry has responded with a tidal surge in new R&D spending. But with checkpoint combos looking iffy, drug hunters have been turning in new directions to find a better combination approach to different cancers. We’ll look at what’s hot - and what’s not - in 2022.
Our panel of veteran industry dealmakers will take a look at the top trends as we enter a new year at the bargaining table. We’ll dig into the full year of deal numbers for 2021 — direct from Chris Dokomajilar at DealForma — and see what they portend for biopharma.
Advancing a novel category of disease-modifying neuro-therapeutics. Executing global partnerships to accelerate clinical development and multi-regional commercialization of novel, disease-modifying therapeutics.
Commercializing novel disease-modifying categories—Evidence-based strategies for advancing the coverage, reimbursement, and prescribing at scale.
Monday
Tuesday
Wednesday
2022 marks the second anniversary of the global pandemic. How have the industry’s top R&D chiefs handled the transition? What worked, what didn’t? And where do we go from here in further improving on the efficiencies — and avoiding the failures — that highlighted the most impactful 2 years this industry has ever seen? And what are the most important new research initiatives planned for 2022?
Monday
Tuesday
Wednesday
If there was one big R&D theme for 2022, it centered on the troubles plaguing the first generation of gene therapy developers. But biotech loves a problem and the potential that creates for innovation. We’ll look at the top innovators in the field and how they’re tackling some of the thorniest issues in drug development today.
The world’s top VCs offer their views of the biotech VC business from a high cruising altitude. Billions have been funneled into startups in just the last year as record funds flow through biotech. Who’s getting financed in 2022? And what does it take to get an A-list syndicate together for a mega-round in 2022?
